Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB8 | P28062 | 1/20 | 0.64 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.64 |
| ▸ | MME | P08473 | 2/20 | 0.61 |
| ▸ | CTSL | P07711 | 1/20 | 0.61 |
| ▸ | LTA4H | P09960 | 1/20 | 0.58 |
| ▸ | ACE | P12821 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.56 |
| ▸ | CNR2 | P34972 | 2/20 | 0.55 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15251753 | 1.00 | PSMB8 (0.64) | PSMB8PSMB5MMECTSLLTA4H | |
| SCHEMBL2368090 | 1.00 | PSMB8 (0.64) | PSMB8PSMB5MMECTSLLTA4H | |
| SCHEMBL9830820 | 0.90 | MME (0.66) | PSMB5MMECTSLLTA4HACE | |
| SCHEMBL9830825 | 0.90 | MME (0.66) | PSMB5MMECTSLLTA4HACE | |
| SCHEMBL24831957 | 0.88 | ALDH1A1 (0.64) | PSMB8PSMB5CTSLFOLH1CNR2 | |
| SCHEMBL9829825 | 0.88 | FOLH1 (0.68) | PSMB8PSMB5MMECTSLACE | |
| SCHEMBL9829831 | 0.88 | FOLH1 (0.68) | PSMB8PSMB5MMECTSLACE | |
| SCHEMBL6941568 | 0.88 | PSMB8 (0.61) | PSMB8PSMB5CTSLPOLBCNR2 | |
| SCHEMBL9831107 | 0.87 | CNR2 (0.57) | PSMB8PSMB5CTSLPOLBFOLH1 | |
| SCHEMBL9831110 | 0.87 | CNR2 (0.57) | PSMB8PSMB5CTSLPOLBFOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 171 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0951464-B1 | N-(ARYL/HETEROARYLACETYL) AMINO ACID ESTERS, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING BETA-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS | ELAN PHARM INC (US) | 2005-05-11 | — | — | EP | claimed |
| CN-1237960-A | N (aryl/heteroarylacetyl) amino acid esters, pharmaceutical compositions comprising same, and method for inhibiting 'beta'-amyloid peptide release and/or its synthesis by use of such compounds | YEELAN PHARMACEUTICAL CORP (US) | 1999-12-08 | — | — | CN | claimed |
| US-20260034084-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | NAVITOR PHARM INC (US) | 2026-02-05 | — | — | US | disclosed |
| US-12427130-B2 | Modulators of Sestrin-GATOR2 interaction and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2025-09-30 | — | — | US | disclosed |
| US-12378263-B2 | Modulators of sestrin-GATOR2 interaction and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2025-08-05 | — | — | US | disclosed |
| EP-3615019-B1 | MODULATOR OF SESTRIN-GATOR2 INTERACTION FOR USE IN THE TREATMENT OF TREATMENT-RESISTANT DEPRESSION | NAVITOR PHARM INC (US) | 2025-06-04 | — | — | EP | disclosed |
| EP-4556069-A2 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | Navitor Pharmaceuticals, Inc. (US) | 2025-05-21 | — | — | EP | disclosed |
| US-20240091184-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. | 2024-03-21 | — | — | US | disclosed |
| CN-114026427-B | Marker for diagnosing kidney disease and diagnostic method | 深圳市中医院 | 2023-11-17 | — | — | CN | disclosed |
| US-20230257388-A1 | GRANZYME B DIRECTED IMAGING AND THERAPY | CYTOSITE BIOPHARMA INC. (US) | 2023-08-17 | — | — | US | disclosed |
| CN-116370448-A | Modulators of SESTRIN-GATOR2 interactions and uses thereof | 纳维托制药有限公司 | 2023-07-04 | — | — | CN | disclosed |
| EP-0453047-B1 | Penicillin G acylase, a gene encoding the same and a method for the production of this enzyme | GIST BROCADES NV (NL) | 1995-07-05 | — | — | EP | disclosed |
| WO-1995015973-A1 | CS-1 PEPTIDOMIMETICS, COMPOSITIONS AND METHODS OF USING THE SAME | CYTEL CORPORATION (US) | 1995-06-15 | — | — | WO | disclosed |
| US-5168048-A | Genetic engineering of Alcaligenes | GIST-BROCADES NV (NL) | 1992-12-01 | — | — | US | disclosed |
| WO-1991016435-A1 | MUTATED BETA-LACTAM ACYLASE GENES | GIST-BROCADES N.V. (NL) | 1991-10-31 | — | — | WO | disclosed |
| EP-0453048-A1 | Mutated beta-lactam acylase genes | GIST-BROCADES N.V. (NL) | 1991-10-23 | — | — | EP | disclosed |
| EP-0453047-A1 | Penicillin G acylase, a gene encoding the same and a method for the production of this enzyme | GIST-BROCADES N.V. (NL) | 1991-10-23 | — | — | EP | disclosed |
| EP-0226304-B1 | COMPOSITION CONTAINING A PENEM OR CARBAPENEM ANTIBIOTIC | SANKYO COMPANY LIMITED (JP) | 1991-08-28 | — | — | EP | disclosed |
| US-4757066-A | Reduces renal toxicity | SANKYO COMPANY LIMITED (JP) | 1988-07-12 | — | — | US | disclosed |
| EP-0226304-A1 | Composition containing a penem or carbapenem antibiotic | SANKYO COMPANY LIMITED (JP) | 1987-06-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260034084-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | RICTOR, RPTOR, MTOR | PSMB8 3512/4885PSMB5 2815/4885MME 4770/4885 |
| US-20230257388-A1 | GRANZYME B DIRECTED IMAGING AND THERAPY | GZMB, PRF1, CTSB | PSMB8 1844/4885PSMB5 2572/4885MME 289/4885 |
| US-20240091184-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | GATD3, GABRR2, GABRR3 | PSMB8 4105/4885PSMB5 4087/4885MME 4472/4885 |
| US-12378263-B2 | Modulators of sestrin-GATOR2 interaction and uses thereof | GATD3, GABRR2, GABRR3 | PSMB8 4105/4885PSMB5 4087/4885MME 4472/4885 |
| US-12427130-B2 | Modulators of Sestrin-GATOR2 interaction and uses thereof | GATD3, GABRR2, GABRR3 | PSMB8 4105/4885PSMB5 4087/4885MME 4472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.